Background
• Neuromuscular blocking agents (NMBAs) are often administered during surgical procedures to provide muscle relaxation and prevent patient movement, which may increase the risk of surgical complications • When neuromuscular block no longer needs to be maintained, patients may either be allowed to spontaneously recover neuromuscular function or be administered a reversal agent for more rapid recovery • Sugammadex is a reversal agent licensed in the European Union, but not yet available in Canada, to reverse neuromuscular blockade induced by the NMBAs rocuronium and vecuronium • In clinical trials, sugammadex produced much more rapid and predictable reversal of neuromuscular block than comparator reversal agent neostigmine and, when quantitative neuromuscular monitoring was not required, a steep reduction in the incidence of residual neuromuscular blockade 1-5 • In addition, sugammadex is effi cacious in rapidly reversing deep levels of neuromuscular blockade, 6-8 whereas neostigmine is not 8,9 • Prior models of sugammadex 10, 11 
Conclusions
• Depending upon neuromuscular management practices, sugammadex can potentially reduce the risk of residual neuromuscular blockade and/or enhance OR effi ciency
• In clinical practice in Canada, the vast majority of patients are not verifi ed to have full neuromuscular recovery (TOF ratio ≥0.9) prior to extubation in the OR 27-28 -Eg, via quantitative neuromuscular monitoring
• Therefore, for the majority of patients currently managed with moderate NMB:
-Principal impact of substituting sugammadex for neostigmine is likely to be a steep reduction in the risk of residual blockade and associated complications • For patients currently managed with deep NMB through the end of the procedure:
-Sugammadex is likely to both enhance OR efficiency and reduce complications of residual block -Where OR efficiency gains occur, potential benefits of sugammadex may include:
• Reduced procedural cancellations due to OR time overrun, avoided staff overtime, and opportunity to evaluate if procedural throughput may be increased
Caveats/Further Research
• For illustration, assume all procedures in OR day used NMBA rocuronium and neostigmine or sugammadex for neuromuscular reversal -Enables full evaluation of potential for sugammadex to impact OR outcomes within a given OR day -In clinical practice, variation may exist across procedures occurring within a given OR on a particular day in terms of whether NMBAs are used and, if so, whether neuromuscular block is reversed using a pharmaceutical agent or allowed to spontaneously reverse • This variation would tend to dilute the impact of sugammadex availability on cumulative outcomes across an entire OR day • Potentially rare, but severe, outcomes of residual neuromuscular block not modeled due to lack of available data • There may be other hospital resource impacts of saved OR time not modeled here -Time for reprepping and rescheduling patients following a cancellation • Possibility of scheduling an additional short procedure when OR time is saved
